nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—PTGIS—decidua—cervical cancer	0.0584	0.0954	CbGeAlD
Epoprostenol—P2RY12—epithelium—cervical cancer	0.0557	0.091	CbGeAlD
Epoprostenol—PTGIS—mammalian vulva—cervical cancer	0.0537	0.0876	CbGeAlD
Epoprostenol—PTGER1—renal system—cervical cancer	0.0533	0.0871	CbGeAlD
Epoprostenol—PTGIS—uterus—cervical cancer	0.0511	0.0835	CbGeAlD
Epoprostenol—PTGIS—female reproductive system—cervical cancer	0.046	0.0751	CbGeAlD
Epoprostenol—PTGER1—female reproductive system—cervical cancer	0.0427	0.0698	CbGeAlD
Epoprostenol—PTGIS—female gonad—cervical cancer	0.0418	0.0683	CbGeAlD
Epoprostenol—PTGER1—female gonad—cervical cancer	0.0389	0.0635	CbGeAlD
Epoprostenol—PTGIR—epithelium—cervical cancer	0.0355	0.058	CbGeAlD
Epoprostenol—PTGIR—renal system—cervical cancer	0.033	0.0538	CbGeAlD
Epoprostenol—PTGIS—lymph node—cervical cancer	0.0269	0.0439	CbGeAlD
Epoprostenol—PTGIR—female reproductive system—cervical cancer	0.0264	0.0431	CbGeAlD
Epoprostenol—PTGIR—female gonad—cervical cancer	0.024	0.0392	CbGeAlD
Epoprostenol—Pleural effusion—Topotecan—cervical cancer	0.0203	0.0587	CcSEcCtD
Epoprostenol—Pulmonary embolism—Topotecan—cervical cancer	0.0155	0.0449	CcSEcCtD
Epoprostenol—PTGIR—lymph node—cervical cancer	0.0154	0.0252	CbGeAlD
Epoprostenol—Sepsis—Topotecan—cervical cancer	0.0135	0.039	CcSEcCtD
Epoprostenol—CYP2C9—female reproductive system—cervical cancer	0.00943	0.0154	CbGeAlD
Epoprostenol—Pancytopenia—Topotecan—cervical cancer	0.00924	0.0268	CcSEcCtD
Epoprostenol—Pneumonia—Topotecan—cervical cancer	0.00873	0.0253	CcSEcCtD
Epoprostenol—Infestation NOS—Topotecan—cervical cancer	0.00868	0.0251	CcSEcCtD
Epoprostenol—Infestation—Topotecan—cervical cancer	0.00868	0.0251	CcSEcCtD
Epoprostenol—Sweating—Topotecan—cervical cancer	0.00832	0.0241	CcSEcCtD
Epoprostenol—Epistaxis—Topotecan—cervical cancer	0.00818	0.0237	CcSEcCtD
Epoprostenol—Haemoglobin—Topotecan—cervical cancer	0.00783	0.0227	CcSEcCtD
Epoprostenol—Rhinitis—Topotecan—cervical cancer	0.00781	0.0226	CcSEcCtD
Epoprostenol—Haemorrhage—Topotecan—cervical cancer	0.00779	0.0226	CcSEcCtD
Epoprostenol—Hypoaesthesia—Topotecan—cervical cancer	0.00775	0.0225	CcSEcCtD
Epoprostenol—Pharyngitis—Topotecan—cervical cancer	0.00773	0.0224	CcSEcCtD
Epoprostenol—Angiopathy—Topotecan—cervical cancer	0.00707	0.0205	CcSEcCtD
Epoprostenol—Mediastinal disorder—Topotecan—cervical cancer	0.00702	0.0203	CcSEcCtD
Epoprostenol—Chills—Topotecan—cervical cancer	0.00699	0.0202	CcSEcCtD
Epoprostenol—Back pain—Topotecan—cervical cancer	0.00656	0.019	CcSEcCtD
Epoprostenol—Muscle spasms—Topotecan—cervical cancer	0.00652	0.0189	CcSEcCtD
Epoprostenol—Anaemia—Topotecan—cervical cancer	0.00627	0.0182	CcSEcCtD
Epoprostenol—Cough—Topotecan—cervical cancer	0.00592	0.0171	CcSEcCtD
Epoprostenol—Arthralgia—Topotecan—cervical cancer	0.00577	0.0167	CcSEcCtD
Epoprostenol—Chest pain—Topotecan—cervical cancer	0.00577	0.0167	CcSEcCtD
Epoprostenol—Myalgia—Topotecan—cervical cancer	0.00577	0.0167	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00573	0.0166	CcSEcCtD
Epoprostenol—Anaphylactic shock—Topotecan—cervical cancer	0.00553	0.016	CcSEcCtD
Epoprostenol—Infection—Topotecan—cervical cancer	0.0055	0.0159	CcSEcCtD
Epoprostenol—Nervous system disorder—Topotecan—cervical cancer	0.00543	0.0157	CcSEcCtD
Epoprostenol—Thrombocytopenia—Topotecan—cervical cancer	0.00542	0.0157	CcSEcCtD
Epoprostenol—Skin disorder—Topotecan—cervical cancer	0.00537	0.0156	CcSEcCtD
Epoprostenol—Hyperhidrosis—Topotecan—cervical cancer	0.00535	0.0155	CcSEcCtD
Epoprostenol—Anorexia—Topotecan—cervical cancer	0.00527	0.0153	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00504	0.0146	CcSEcCtD
Epoprostenol—Paraesthesia—Topotecan—cervical cancer	0.00497	0.0144	CcSEcCtD
Epoprostenol—Dyspnoea—Topotecan—cervical cancer	0.00493	0.0143	CcSEcCtD
Epoprostenol—Dyspepsia—Topotecan—cervical cancer	0.00487	0.0141	CcSEcCtD
Epoprostenol—Decreased appetite—Topotecan—cervical cancer	0.00481	0.0139	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Topotecan—cervical cancer	0.00478	0.0138	CcSEcCtD
Epoprostenol—Fatigue—Topotecan—cervical cancer	0.00477	0.0138	CcSEcCtD
Epoprostenol—Pain—Topotecan—cervical cancer	0.00473	0.0137	CcSEcCtD
Epoprostenol—Constipation—Topotecan—cervical cancer	0.00473	0.0137	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Topotecan—cervical cancer	0.00452	0.0131	CcSEcCtD
Epoprostenol—Urticaria—Topotecan—cervical cancer	0.0044	0.0127	CcSEcCtD
Epoprostenol—Abdominal pain—Topotecan—cervical cancer	0.00437	0.0127	CcSEcCtD
Epoprostenol—Body temperature increased—Topotecan—cervical cancer	0.00437	0.0127	CcSEcCtD
Epoprostenol—Hypersensitivity—Topotecan—cervical cancer	0.00408	0.0118	CcSEcCtD
Epoprostenol—Asthenia—Topotecan—cervical cancer	0.00397	0.0115	CcSEcCtD
Epoprostenol—Pruritus—Topotecan—cervical cancer	0.00392	0.0113	CcSEcCtD
Epoprostenol—Diarrhoea—Topotecan—cervical cancer	0.00379	0.011	CcSEcCtD
Epoprostenol—Dizziness—Topotecan—cervical cancer	0.00366	0.0106	CcSEcCtD
Epoprostenol—Vomiting—Topotecan—cervical cancer	0.00352	0.0102	CcSEcCtD
Epoprostenol—Rash—Topotecan—cervical cancer	0.00349	0.0101	CcSEcCtD
Epoprostenol—Dermatitis—Topotecan—cervical cancer	0.00349	0.0101	CcSEcCtD
Epoprostenol—Headache—Topotecan—cervical cancer	0.00347	0.01	CcSEcCtD
Epoprostenol—Nausea—Topotecan—cervical cancer	0.00329	0.00952	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.0025	0.0588	CbGpPWpGaD
Epoprostenol—PTGIR—G alpha (s) signalling events—TAAR6—cervical cancer	0.00242	0.0569	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.00219	0.0514	CbGpPWpGaD
Epoprostenol—PTGIS—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—cervical cancer	0.00132	0.0309	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—GP6—cervical cancer	0.00129	0.0303	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—SERPIND1—cervical cancer	0.00129	0.0303	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.00126	0.0295	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—SERPIND1—cervical cancer	0.00119	0.0279	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—GP6—cervical cancer	0.00119	0.0279	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.00116	0.0271	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.00116	0.0271	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—GP5—cervical cancer	0.00113	0.0265	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—GP5—cervical cancer	0.00104	0.0244	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—TAAR6—cervical cancer	0.000957	0.0224	CbGpPWpGaD
Epoprostenol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000945	0.0222	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—TAAR6—cervical cancer	0.00088	0.0207	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—TAAR6—cervical cancer	0.00088	0.0207	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—WNT2—cervical cancer	0.000747	0.0175	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—WNT2—cervical cancer	0.000687	0.0161	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—WNT2—cervical cancer	0.000687	0.0161	CbGpPWpGaD
Epoprostenol—PTGIR—Thromboxane A2 receptor signaling—EGFR—cervical cancer	0.00062	0.0145	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—WNT5A—cervical cancer	0.000566	0.0133	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—CTNNB1—cervical cancer	0.000545	0.0128	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—TAAR6—cervical cancer	0.000541	0.0127	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—WNT5A—cervical cancer	0.000521	0.0122	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—WNT5A—cervical cancer	0.000521	0.0122	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—TAAR6—cervical cancer	0.000497	0.0117	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—TAAR6—cervical cancer	0.000497	0.0117	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—TAAR6—cervical cancer	0.000491	0.0115	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—STAT3—cervical cancer	0.000475	0.0111	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—TAAR6—cervical cancer	0.000452	0.0106	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—TAAR6—cervical cancer	0.000452	0.0106	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—WNT2—cervical cancer	0.000406	0.00954	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—WNT2—cervical cancer	0.000383	0.00899	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—AKAP13—cervical cancer	0.00037	0.00869	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—WNT2—cervical cancer	0.000353	0.00827	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—WNT2—cervical cancer	0.000353	0.00827	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—AKAP13—cervical cancer	0.000341	0.008	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—AKAP13—cervical cancer	0.000341	0.008	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—AKAP13—cervical cancer	0.000336	0.00789	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CA9—cervical cancer	0.000321	0.00754	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—AKAP13—cervical cancer	0.00031	0.00726	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—AKAP13—cervical cancer	0.00031	0.00726	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—WNT5A—cervical cancer	0.000308	0.00723	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—WNT5A—cervical cancer	0.00029	0.00681	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TAAR6—cervical cancer	0.00029	0.0068	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—WNT5A—cervical cancer	0.000267	0.00627	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—WNT5A—cervical cancer	0.000267	0.00627	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TAAR6—cervical cancer	0.000267	0.00626	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TAAR6—cervical cancer	0.000267	0.00626	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—WNT2—cervical cancer	0.000226	0.00531	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	0.000211	0.00495	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—WNT2—cervical cancer	0.000208	0.00489	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—WNT2—cervical cancer	0.000208	0.00489	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AKAP13—cervical cancer	0.000199	0.00466	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKAP13—cervical cancer	0.000183	0.00429	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKAP13—cervical cancer	0.000183	0.00429	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HES1—cervical cancer	0.000177	0.00416	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—WNT5A—cervical cancer	0.000172	0.00402	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—WNT5A—cervical cancer	0.000158	0.0037	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—WNT5A—cervical cancer	0.000158	0.0037	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MTHFR—cervical cancer	0.000156	0.00365	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TERT—cervical cancer	0.000155	0.00364	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—FGFR3—cervical cancer	0.000143	0.00334	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—NOTCH1—cervical cancer	0.000134	0.00314	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—MTHFR—cervical cancer	0.00013	0.00306	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NOTCH2—cervical cancer	0.00012	0.00282	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NOTCH2—cervical cancer	0.000111	0.0026	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NOTCH2—cervical cancer	0.000111	0.0026	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MTOR—cervical cancer	0.0001	0.00235	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CD4—cervical cancer	0.0001	0.00235	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HES1—cervical cancer	9.87e-05	0.00232	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TP53—cervical cancer	9.71e-05	0.00228	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HES1—cervical cancer	9.09e-05	0.00213	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HES1—cervical cancer	9.09e-05	0.00213	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TP53—cervical cancer	8.94e-05	0.0021	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CTNNB1—cervical cancer	8.89e-05	0.00209	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TERT—cervical cancer	8.65e-05	0.00203	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TERT—cervical cancer	7.96e-05	0.00187	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TERT—cervical cancer	7.96e-05	0.00187	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—FGFR3—cervical cancer	7.94e-05	0.00186	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—STAT3—cervical cancer	7.75e-05	0.00182	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NOTCH1—cervical cancer	7.45e-05	0.00175	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—FGFR3—cervical cancer	7.31e-05	0.00171	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—FGFR3—cervical cancer	7.31e-05	0.00171	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—EGFR—cervical cancer	7.04e-05	0.00165	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NOTCH1—cervical cancer	6.86e-05	0.00161	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NOTCH1—cervical cancer	6.86e-05	0.00161	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—EGFR—cervical cancer	6.64e-05	0.00156	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—EGFR—cervical cancer	6.11e-05	0.00143	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—EGFR—cervical cancer	6.11e-05	0.00143	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MTOR—cervical cancer	5.58e-05	0.00131	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CA9—cervical cancer	5.19e-05	0.00122	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MTOR—cervical cancer	5.14e-05	0.00121	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MTOR—cervical cancer	5.14e-05	0.00121	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CASP3—cervical cancer	5.14e-05	0.00121	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CTNNB1—cervical cancer	4.95e-05	0.00116	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CASP3—cervical cancer	4.73e-05	0.00111	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CASP3—cervical cancer	4.73e-05	0.00111	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CTNNB1—cervical cancer	4.56e-05	0.00107	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CTNNB1—cervical cancer	4.56e-05	0.00107	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—STAT3—cervical cancer	4.32e-05	0.00101	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—STAT3—cervical cancer	3.97e-05	0.000932	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—STAT3—cervical cancer	3.97e-05	0.000932	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EGFR—cervical cancer	3.92e-05	0.00092	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EGFR—cervical cancer	3.61e-05	0.000847	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EGFR—cervical cancer	3.61e-05	0.000847	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—cervical cancer	3.29e-05	0.000773	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—cervical cancer	3.03e-05	0.000711	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—cervical cancer	3.03e-05	0.000711	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MTHFR—cervical cancer	2.11e-05	0.000494	CbGpPWpGaD
